| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 15 | 2017 | 763 | 2.530 |
Why?
|
| Myelodysplastic Syndromes | 10 | 2017 | 346 | 1.760 |
Why?
|
| Haploinsufficiency | 5 | 2017 | 62 | 1.220 |
Why?
|
| Wnt Signaling Pathway | 2 | 2017 | 94 | 1.070 |
Why?
|
| Chromosome Deletion | 6 | 2014 | 229 | 1.070 |
Why?
|
| Genes, APC | 2 | 2017 | 26 | 1.060 |
Why?
|
| Chromosome Aberrations | 4 | 2017 | 387 | 0.980 |
Why?
|
| Early Growth Response Protein 1 | 2 | 2013 | 54 | 0.940 |
Why?
|
| Neoplasm Proteins | 4 | 2016 | 534 | 0.790 |
Why?
|
| Cell Transformation, Neoplastic | 6 | 2016 | 428 | 0.760 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2016 | 90 | 0.660 |
Why?
|
| Translocation, Genetic | 12 | 2016 | 265 | 0.630 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2017 | 154 | 0.620 |
Why?
|
| Chromosomes, Human, Pair 5 | 2 | 2017 | 109 | 0.610 |
Why?
|
| Stem Cell Niche | 1 | 2017 | 21 | 0.590 |
Why?
|
| Oncogene Proteins, Fusion | 4 | 2016 | 128 | 0.570 |
Why?
|
| Retroviridae | 2 | 2017 | 79 | 0.570 |
Why?
|
| MicroRNAs | 3 | 2016 | 535 | 0.570 |
Why?
|
| Gene-Environment Interaction | 1 | 2017 | 103 | 0.560 |
Why?
|
| Peptide Termination Factors | 1 | 2016 | 5 | 0.560 |
Why?
|
| Leukemia, Radiation-Induced | 1 | 2015 | 14 | 0.550 |
Why?
|
| Neoplasms, Second Primary | 2 | 2017 | 252 | 0.530 |
Why?
|
| Mutagenesis, Insertional | 1 | 2016 | 111 | 0.530 |
Why?
|
| Wnt Proteins | 1 | 2015 | 124 | 0.520 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2016 | 382 | 0.480 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2013 | 40 | 0.460 |
Why?
|
| Genes, p53 | 1 | 2013 | 109 | 0.460 |
Why?
|
| Carcinogenesis | 1 | 2015 | 196 | 0.450 |
Why?
|
| Mice, Transgenic | 7 | 2016 | 1557 | 0.440 |
Why?
|
| Mice | 19 | 2017 | 11439 | 0.440 |
Why?
|
| Leukemia, Promyelocytic, Acute | 3 | 2003 | 49 | 0.440 |
Why?
|
| Carrier Proteins | 1 | 2015 | 675 | 0.410 |
Why?
|
| Nerve Tissue Proteins | 1 | 2015 | 504 | 0.410 |
Why?
|
| Mice, Inbred C57BL | 8 | 2017 | 3112 | 0.410 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2013 | 382 | 0.390 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2017 | 2271 | 0.380 |
Why?
|
| Proteins | 2 | 2016 | 777 | 0.380 |
Why?
|
| Mutation | 7 | 2017 | 3978 | 0.370 |
Why?
|
| Leukemia, Myeloid | 6 | 2016 | 249 | 0.370 |
Why?
|
| Animals | 26 | 2017 | 26652 | 0.340 |
Why?
|
| Leukemia | 5 | 2006 | 320 | 0.320 |
Why?
|
| Mice, Knockout | 4 | 2017 | 1944 | 0.320 |
Why?
|
| Antineoplastic Agents | 3 | 2017 | 2360 | 0.310 |
Why?
|
| Chromosomes, Human, Pair 7 | 4 | 2017 | 79 | 0.310 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2016 | 157 | 0.290 |
Why?
|
| Chromosomes, Human, Pair 21 | 5 | 2015 | 54 | 0.290 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 5 | 2015 | 173 | 0.270 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 2438 | 0.260 |
Why?
|
| Prognosis | 5 | 2017 | 3639 | 0.250 |
Why?
|
| Erythroblasts | 2 | 2015 | 25 | 0.250 |
Why?
|
| Humans | 55 | 2020 | 85796 | 0.240 |
Why?
|
| Myeloproliferative Disorders | 2 | 2016 | 110 | 0.240 |
Why?
|
| beta Catenin | 2 | 2017 | 255 | 0.230 |
Why?
|
| Chromosomes, Human, Pair 17 | 4 | 2002 | 110 | 0.220 |
Why?
|
| Bone Marrow | 6 | 2016 | 435 | 0.210 |
Why?
|
| Chromosomes, Human, Pair 8 | 3 | 2015 | 85 | 0.190 |
Why?
|
| Bone Marrow Cells | 3 | 2017 | 253 | 0.180 |
Why?
|
| Hematopoiesis | 2 | 2017 | 164 | 0.170 |
Why?
|
| Base Sequence | 20 | 2016 | 2334 | 0.170 |
Why?
|
| Chromosome Mapping | 17 | 2001 | 1073 | 0.170 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2016 | 375 | 0.160 |
Why?
|
| Transcription Factors | 5 | 2016 | 1580 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 11 | 6 | 2006 | 106 | 0.150 |
Why?
|
| DNA-Binding Proteins | 5 | 2016 | 1214 | 0.150 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2017 | 138 | 0.150 |
Why?
|
| Disease Models, Animal | 4 | 2017 | 2241 | 0.150 |
Why?
|
| Radiation Exposure | 1 | 2017 | 23 | 0.150 |
Why?
|
| Pyrvinium Compounds | 1 | 2017 | 5 | 0.150 |
Why?
|
| Diphenylamine | 1 | 2017 | 4 | 0.150 |
Why?
|
| MAP Kinase Signaling System | 2 | 2017 | 193 | 0.150 |
Why?
|
| Clone Cells | 1 | 2017 | 213 | 0.150 |
Why?
|
| Mice, 129 Strain | 1 | 2017 | 55 | 0.150 |
Why?
|
| Cellular Senescence | 2 | 2014 | 94 | 0.150 |
Why?
|
| Genomic Instability | 2 | 2015 | 79 | 0.150 |
Why?
|
| Gene Expression Regulation | 4 | 2016 | 1928 | 0.150 |
Why?
|
| Karyotyping | 7 | 2003 | 250 | 0.140 |
Why?
|
| Molecular Sequence Data | 20 | 2013 | 3034 | 0.140 |
Why?
|
| DNA Methylation | 3 | 2016 | 630 | 0.140 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2016 | 456 | 0.140 |
Why?
|
| Genetic Markers | 3 | 2000 | 476 | 0.140 |
Why?
|
| Tandem Repeat Sequences | 1 | 2016 | 26 | 0.140 |
Why?
|
| Penetrance | 1 | 2016 | 44 | 0.140 |
Why?
|
| Hemoglobinuria, Paroxysmal | 1 | 2015 | 5 | 0.140 |
Why?
|
| Benzamides | 1 | 2017 | 229 | 0.140 |
Why?
|
| Cell Differentiation | 4 | 2015 | 1471 | 0.140 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2016 | 57 | 0.140 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2014 | 292 | 0.130 |
Why?
|
| Mice, Mutant Strains | 1 | 2016 | 231 | 0.130 |
Why?
|
| Genes, abl | 1 | 2015 | 12 | 0.130 |
Why?
|
| Anemia | 1 | 2016 | 124 | 0.130 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2016 | 127 | 0.130 |
Why?
|
| GTPase-Activating Proteins | 1 | 2015 | 65 | 0.130 |
Why?
|
| TATA Box Binding Protein-Like Proteins | 1 | 2014 | 1 | 0.130 |
Why?
|
| NIH 3T3 Cells | 1 | 2015 | 105 | 0.130 |
Why?
|
| Lamin Type A | 1 | 2014 | 24 | 0.130 |
Why?
|
| Genes, BRCA2 | 1 | 2015 | 160 | 0.120 |
Why?
|
| Chromosomes, Human | 1 | 2014 | 66 | 0.120 |
Why?
|
| Genes, BRCA1 | 1 | 2015 | 192 | 0.120 |
Why?
|
| BRCA1 Protein | 1 | 2015 | 200 | 0.120 |
Why?
|
| Histone-Lysine N-Methyltransferase | 2 | 2014 | 154 | 0.120 |
Why?
|
| Anemia, Macrocytic | 1 | 2013 | 5 | 0.120 |
Why?
|
| Survivors | 1 | 2015 | 227 | 0.120 |
Why?
|
| Alleles | 3 | 2013 | 1128 | 0.120 |
Why?
|
| Ethylnitrosourea | 1 | 2013 | 30 | 0.120 |
Why?
|
| Genes, Lethal | 1 | 2013 | 53 | 0.120 |
Why?
|
| Cellular Microenvironment | 1 | 2013 | 28 | 0.120 |
Why?
|
| Female | 17 | 2016 | 44218 | 0.120 |
Why?
|
| Erythropoiesis | 1 | 2013 | 51 | 0.120 |
Why?
|
| DNA Replication | 1 | 2014 | 164 | 0.120 |
Why?
|
| Mutation, Missense | 1 | 2015 | 276 | 0.110 |
Why?
|
| Mice, Nude | 1 | 2015 | 791 | 0.110 |
Why?
|
| Germ-Line Mutation | 1 | 2015 | 330 | 0.110 |
Why?
|
| Male | 19 | 2020 | 40654 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 1 | 3 | 2000 | 100 | 0.110 |
Why?
|
| Heterozygote | 1 | 2013 | 366 | 0.110 |
Why?
|
| Age Factors | 3 | 2015 | 1828 | 0.110 |
Why?
|
| Stress, Physiological | 1 | 2014 | 227 | 0.110 |
Why?
|
| Spleen | 1 | 2013 | 430 | 0.110 |
Why?
|
| Gene Deletion | 1 | 2013 | 337 | 0.110 |
Why?
|
| Genotype | 2 | 2016 | 1848 | 0.110 |
Why?
|
| Philadelphia Chromosome | 1 | 1992 | 38 | 0.110 |
Why?
|
| Cloning, Molecular | 12 | 2001 | 646 | 0.110 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2014 | 279 | 0.100 |
Why?
|
| Hematologic Neoplasms | 1 | 2015 | 329 | 0.100 |
Why?
|
| Survival Rate | 2 | 2015 | 1849 | 0.100 |
Why?
|
| Lymphoma | 1 | 2013 | 262 | 0.100 |
Why?
|
| Registries | 1 | 2015 | 702 | 0.100 |
Why?
|
| Apoptosis | 3 | 2013 | 1690 | 0.100 |
Why?
|
| Lymphocyte Activation | 2 | 2013 | 733 | 0.100 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 1938 | 0.090 |
Why?
|
| Gene Expression Profiling | 3 | 2016 | 1388 | 0.090 |
Why?
|
| Risk Factors | 2 | 2017 | 5251 | 0.090 |
Why?
|
| Membrane Proteins | 1 | 2016 | 1200 | 0.090 |
Why?
|
| Cells, Cultured | 2 | 2013 | 2836 | 0.090 |
Why?
|
| Risk Assessment | 2 | 2015 | 2213 | 0.080 |
Why?
|
| Colorectal Neoplasms | 1 | 2017 | 937 | 0.080 |
Why?
|
| In Situ Hybridization, Fluorescence | 7 | 2014 | 349 | 0.080 |
Why?
|
| T-Lymphocytes | 2 | 2013 | 1200 | 0.080 |
Why?
|
| Cell Survival | 2 | 2013 | 972 | 0.070 |
Why?
|
| Amino Acid Sequence | 8 | 2016 | 2065 | 0.070 |
Why?
|
| Restriction Mapping | 7 | 1994 | 157 | 0.070 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2005 | 40 | 0.070 |
Why?
|
| Adult | 13 | 2016 | 25522 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 16 | 2 | 1996 | 79 | 0.070 |
Why?
|
| Receptors, Androgen | 1 | 2005 | 113 | 0.060 |
Why?
|
| Androgens | 1 | 2005 | 167 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2005 | 122 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 7 | 1997 | 929 | 0.060 |
Why?
|
| Middle Aged | 9 | 2020 | 24742 | 0.060 |
Why?
|
| DNA, Neoplasm | 6 | 1997 | 265 | 0.060 |
Why?
|
| RNA, Messenger | 5 | 2006 | 1987 | 0.060 |
Why?
|
| Chromosome Disorders | 1 | 1984 | 114 | 0.060 |
Why?
|
| Genes | 3 | 1994 | 305 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2006 | 1200 | 0.060 |
Why?
|
| Genes, Homeobox | 2 | 1995 | 81 | 0.060 |
Why?
|
| Cell Division | 2 | 2003 | 693 | 0.060 |
Why?
|
| DNA, Complementary | 6 | 2006 | 394 | 0.060 |
Why?
|
| Homeodomain Proteins | 3 | 2014 | 538 | 0.050 |
Why?
|
| Aged | 6 | 2015 | 18161 | 0.050 |
Why?
|
| Retrospective Studies | 1 | 2015 | 8466 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2002 | 63 | 0.050 |
Why?
|
| Histones | 2 | 2014 | 311 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2017 | 592 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2015 | 2904 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 2 | 3 | 1996 | 85 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2002 | 189 | 0.050 |
Why?
|
| Prostatic Neoplasms | 2 | 2005 | 1721 | 0.050 |
Why?
|
| Cell Line | 5 | 2016 | 2474 | 0.050 |
Why?
|
| Cell Line, Tumor | 2 | 2017 | 2433 | 0.050 |
Why?
|
| Genetic Linkage | 2 | 2000 | 623 | 0.050 |
Why?
|
| Chromosome Banding | 4 | 1993 | 74 | 0.050 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 1 | 2000 | 9 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2000 | 44 | 0.050 |
Why?
|
| Acute Disease | 3 | 2016 | 827 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 9 | 2 | 2006 | 86 | 0.040 |
Why?
|
| DNA | 6 | 1995 | 1294 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2016 | 1598 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 3 | 1998 | 943 | 0.040 |
Why?
|
| Recurrence | 1 | 2002 | 1136 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 5 | 2005 | 1041 | 0.040 |
Why?
|
| Linkage Disequilibrium | 1 | 2000 | 472 | 0.040 |
Why?
|
| Gene Expression | 4 | 1995 | 1286 | 0.040 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2001 | 276 | 0.040 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 2 | 2014 | 72 | 0.040 |
Why?
|
| Muscle Proteins | 1 | 1998 | 133 | 0.040 |
Why?
|
| Disease Progression | 2 | 2016 | 1458 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2020 | 930 | 0.040 |
Why?
|
| Chromosome Breakpoints | 1 | 2016 | 15 | 0.040 |
Why?
|
| Clonal Evolution | 1 | 2017 | 15 | 0.040 |
Why?
|
| Carbohydrate Dehydrogenases | 1 | 1996 | 4 | 0.040 |
Why?
|
| Receptors, Cytoadhesin | 1 | 1996 | 2 | 0.040 |
Why?
|
| Microfilament Proteins | 1 | 1998 | 209 | 0.040 |
Why?
|
| Leukopenia | 1 | 2016 | 65 | 0.040 |
Why?
|
| Pseudogenes | 1 | 1996 | 35 | 0.040 |
Why?
|
| Mastocytosis | 1 | 2016 | 13 | 0.040 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 1996 | 16 | 0.040 |
Why?
|
| Blotting, Southern | 5 | 1995 | 129 | 0.030 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2016 | 107 | 0.030 |
Why?
|
| Genes, Neoplasm | 1 | 2016 | 37 | 0.030 |
Why?
|
| Karyotype | 1 | 2016 | 33 | 0.030 |
Why?
|
| Proto-Oncogenes | 1 | 1996 | 61 | 0.030 |
Why?
|
| Integrins | 1 | 1996 | 76 | 0.030 |
Why?
|
| Leukemic Infiltration | 1 | 2015 | 14 | 0.030 |
Why?
|
| Down Syndrome | 1 | 2016 | 54 | 0.030 |
Why?
|
| Helix-Loop-Helix Motifs | 1 | 1995 | 25 | 0.030 |
Why?
|
| Pancytopenia | 1 | 2015 | 23 | 0.030 |
Why?
|
| Anemia, Aplastic | 1 | 2015 | 30 | 0.030 |
Why?
|
| Calmodulin-Binding Proteins | 1 | 2015 | 20 | 0.030 |
Why?
|
| Chicago | 1 | 2020 | 1378 | 0.030 |
Why?
|
| Bone Marrow Diseases | 1 | 2015 | 40 | 0.030 |
Why?
|
| World Health Organization | 1 | 2016 | 102 | 0.030 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2015 | 48 | 0.030 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 2 | 1994 | 135 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 1996 | 125 | 0.030 |
Why?
|
| Myeloid Cells | 1 | 2016 | 98 | 0.030 |
Why?
|
| Glutamine-Fructose-6-Phosphate Transaminase (Isomerizing) | 1 | 1995 | 4 | 0.030 |
Why?
|
| Eosinophilia | 1 | 2016 | 84 | 0.030 |
Why?
|
| Cellular Reprogramming Techniques | 1 | 2015 | 6 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2015 | 220 | 0.030 |
Why?
|
| U937 Cells | 1 | 2015 | 32 | 0.030 |
Why?
|
| K562 Cells | 1 | 2015 | 44 | 0.030 |
Why?
|
| Gene Rearrangement | 2 | 1993 | 170 | 0.030 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 53 | 0.030 |
Why?
|
| Thrombocytopenia | 1 | 2016 | 183 | 0.030 |
Why?
|
| Chromosome Inversion | 1 | 1995 | 47 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2016 | 218 | 0.030 |
Why?
|
| Progeria | 1 | 2014 | 5 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2016 | 368 | 0.030 |
Why?
|
| Clathrin | 1 | 1994 | 29 | 0.030 |
Why?
|
| Nucleic Acid Hybridization | 2 | 1992 | 245 | 0.030 |
Why?
|
| Minichromosome Maintenance Proteins | 1 | 2014 | 2 | 0.030 |
Why?
|
| Adolescent | 6 | 2016 | 8959 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2016 | 280 | 0.030 |
Why?
|
| Nanoparticles | 1 | 2016 | 157 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2016 | 250 | 0.030 |
Why?
|
| DNA, Ribosomal | 1 | 2014 | 44 | 0.030 |
Why?
|
| Azacitidine | 1 | 2015 | 137 | 0.030 |
Why?
|
| Microbodies | 1 | 1994 | 7 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2016 | 508 | 0.030 |
Why?
|
| Azepines | 1 | 2014 | 22 | 0.030 |
Why?
|
| Myosins | 1 | 1995 | 90 | 0.030 |
Why?
|
| Zebrafish Proteins | 1 | 2015 | 145 | 0.030 |
Why?
|
| Genes, RAG-1 | 1 | 2013 | 13 | 0.030 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2014 | 22 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2016 | 617 | 0.030 |
Why?
|
| T Cell Transcription Factor 1 | 1 | 2013 | 23 | 0.030 |
Why?
|
| Thymocytes | 1 | 2013 | 30 | 0.030 |
Why?
|
| Telomere | 1 | 2014 | 110 | 0.030 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 1 | 1993 | 24 | 0.030 |
Why?
|
| Oxidoreductases | 1 | 1994 | 112 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2020 | 2738 | 0.030 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2000 | 548 | 0.030 |
Why?
|
| Microcephaly | 1 | 1994 | 75 | 0.030 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 1 | 2013 | 80 | 0.030 |
Why?
|
| Triazoles | 1 | 2014 | 96 | 0.030 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2013 | 64 | 0.030 |
Why?
|
| Phenotype | 2 | 2015 | 2389 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 1997 | 1054 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2014 | 207 | 0.030 |
Why?
|
| Blast Crisis | 1 | 1993 | 33 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 1993 | 54 | 0.030 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1993 | 44 | 0.030 |
Why?
|
| DNA Primers | 3 | 2001 | 545 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 1993 | 42 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 1993 | 49 | 0.030 |
Why?
|
| Interferon-alpha | 1 | 1993 | 234 | 0.030 |
Why?
|
| Zebrafish | 1 | 2015 | 310 | 0.030 |
Why?
|
| RNA Interference | 1 | 2014 | 369 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1993 | 100 | 0.030 |
Why?
|
| Intellectual Disability | 1 | 1994 | 186 | 0.030 |
Why?
|
| Mitochondria | 1 | 1996 | 536 | 0.030 |
Why?
|
| DNA Damage | 1 | 2014 | 366 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 1993 | 102 | 0.030 |
Why?
|
| Actins | 1 | 2015 | 451 | 0.030 |
Why?
|
| Abnormalities, Multiple | 1 | 1994 | 232 | 0.030 |
Why?
|
| Polymorphism, Genetic | 2 | 1993 | 818 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 549 | 0.030 |
Why?
|
| Biopsy | 1 | 2016 | 1163 | 0.030 |
Why?
|
| Child | 4 | 2016 | 6930 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2016 | 482 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2014 | 731 | 0.030 |
Why?
|
| Serine Endopeptidases | 1 | 1992 | 145 | 0.030 |
Why?
|
| DNA Repair | 1 | 2013 | 356 | 0.030 |
Why?
|
| Recombination, Genetic | 1 | 2013 | 439 | 0.030 |
Why?
|
| Blood Cells | 1 | 1991 | 33 | 0.030 |
Why?
|
| In Situ Hybridization | 3 | 1998 | 310 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2013 | 1060 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2014 | 405 | 0.020 |
Why?
|
| Hominidae | 1 | 1992 | 96 | 0.020 |
Why?
|
| Gene Library | 2 | 2006 | 131 | 0.020 |
Why?
|
| RNA | 3 | 2006 | 560 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2006 | 197 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2014 | 707 | 0.020 |
Why?
|
| Exons | 3 | 1996 | 452 | 0.020 |
Why?
|
| Phosphatidylinositols | 1 | 1989 | 21 | 0.020 |
Why?
|
| Glycolipids | 1 | 1989 | 29 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 1989 | 103 | 0.020 |
Why?
|
| Neoplasms | 1 | 1984 | 2895 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2001 | 416 | 0.020 |
Why?
|
| Child, Preschool | 4 | 2000 | 3612 | 0.020 |
Why?
|
| Transcription, Genetic | 3 | 1998 | 1137 | 0.020 |
Why?
|
| Lod Score | 2 | 2000 | 152 | 0.020 |
Why?
|
| Time Factors | 3 | 2006 | 5178 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 1989 | 429 | 0.020 |
Why?
|
| Lewis X Antigen | 1 | 2006 | 9 | 0.020 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2006 | 15 | 0.020 |
Why?
|
| Expressed Sequence Tags | 1 | 2006 | 35 | 0.020 |
Why?
|
| Castration | 1 | 2005 | 41 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 1994 | 1137 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2016 | 3264 | 0.020 |
Why?
|
| Genetic Engineering | 1 | 2005 | 115 | 0.020 |
Why?
|
| Remission Induction | 2 | 2000 | 722 | 0.020 |
Why?
|
| Young Adult | 1 | 2016 | 5961 | 0.020 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2005 | 124 | 0.020 |
Why?
|
| Biological Evolution | 1 | 1992 | 919 | 0.020 |
Why?
|
| Introns | 2 | 1996 | 290 | 0.020 |
Why?
|
| Oncogenes | 1 | 1984 | 88 | 0.010 |
Why?
|
| Recombinant Proteins | 2 | 1998 | 1018 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 692 | 0.010 |
Why?
|
| Stem Cells | 1 | 2005 | 358 | 0.010 |
Why?
|
| Computational Biology | 1 | 2006 | 528 | 0.010 |
Why?
|
| Blotting, Northern | 2 | 1991 | 258 | 0.010 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2001 | 41 | 0.010 |
Why?
|
| Catalysis | 1 | 2001 | 203 | 0.010 |
Why?
|
| Mutagenesis | 1 | 2001 | 200 | 0.010 |
Why?
|
| X Chromosome | 1 | 2001 | 152 | 0.010 |
Why?
|
| Middle East | 1 | 2000 | 17 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2001 | 280 | 0.010 |
Why?
|
| Physical Chromosome Mapping | 1 | 2000 | 27 | 0.010 |
Why?
|
| Rats | 2 | 1997 | 3998 | 0.010 |
Why?
|
| Family Health | 1 | 2000 | 162 | 0.010 |
Why?
|
| COS Cells | 1 | 1998 | 166 | 0.010 |
Why?
|
| Luciferases | 1 | 1998 | 119 | 0.010 |
Why?
|
| Haplotypes | 1 | 2000 | 639 | 0.010 |
Why?
|
| Organ Specificity | 1 | 1998 | 263 | 0.010 |
Why?
|
| Dogs | 1 | 1998 | 677 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 1997 | 152 | 0.010 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 1996 | 27 | 0.010 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 1998 | 240 | 0.010 |
Why?
|
| Muscle, Smooth | 1 | 1998 | 354 | 0.010 |
Why?
|
| CD11 Antigens | 1 | 1996 | 14 | 0.010 |
Why?
|
| Integrin alpha Chains | 1 | 1996 | 15 | 0.010 |
Why?
|
| Transfection | 1 | 1998 | 899 | 0.010 |
Why?
|
| Lymphocytes | 1 | 1998 | 465 | 0.010 |
Why?
|
| Hybrid Cells | 1 | 1994 | 71 | 0.010 |
Why?
|
| Consensus Sequence | 1 | 1994 | 64 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 1994 | 48 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 1994 | 65 | 0.010 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 1995 | 136 | 0.010 |
Why?
|
| Acyl-CoA Oxidase | 1 | 1994 | 4 | 0.010 |
Why?
|
| RNA, Transfer, Leu | 1 | 1994 | 11 | 0.010 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 1995 | 168 | 0.010 |
Why?
|
| Reference Values | 1 | 1995 | 663 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 1997 | 985 | 0.010 |
Why?
|
| Trisomy | 1 | 1994 | 55 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1994 | 147 | 0.010 |
Why?
|
| Glucokinase | 1 | 1994 | 61 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2000 | 2381 | 0.010 |
Why?
|
| Leucine | 1 | 1993 | 67 | 0.010 |
Why?
|
| Gene Rearrangement, B-Lymphocyte | 1 | 1993 | 37 | 0.010 |
Why?
|
| Sex Factors | 1 | 1997 | 1041 | 0.010 |
Why?
|
| Chromosome Walking | 1 | 1993 | 2 | 0.010 |
Why?
|
| Deoxyribonuclease EcoRI | 1 | 1993 | 7 | 0.010 |
Why?
|
| Immunoglobulin Joining Region | 1 | 1993 | 13 | 0.010 |
Why?
|
| Fatty Acids | 1 | 1994 | 130 | 0.010 |
Why?
|
| RNA Splicing | 1 | 1994 | 142 | 0.010 |
Why?
|
| Deoxyribonuclease BamHI | 1 | 1993 | 2 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1993 | 211 | 0.010 |
Why?
|
| Survival Analysis | 1 | 1997 | 1532 | 0.010 |
Why?
|
| Infant | 1 | 2000 | 3051 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1993 | 126 | 0.010 |
Why?
|
| DNA Probes | 1 | 1993 | 77 | 0.010 |
Why?
|
| Head | 1 | 1994 | 132 | 0.010 |
Why?
|
| Chimera | 1 | 1993 | 56 | 0.010 |
Why?
|
| Syndrome | 1 | 1994 | 445 | 0.010 |
Why?
|
| Binding Sites | 1 | 1995 | 1104 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 1996 | 853 | 0.010 |
Why?
|
| Proprotein Convertase 2 | 1 | 1992 | 11 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 1993 | 206 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 1992 | 32 | 0.010 |
Why?
|
| Poly A | 1 | 1991 | 23 | 0.010 |
Why?
|
| Pedigree | 1 | 1994 | 965 | 0.010 |
Why?
|
| Protein Precursors | 1 | 1992 | 143 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 1991 | 88 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1991 | 137 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2000 | 2354 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 1992 | 352 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 1997 | 3591 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 1997 | 1465 | 0.010 |
Why?
|
| CD58 Antigens | 1 | 1989 | 5 | 0.010 |
Why?
|
| CD48 Antigen | 1 | 1989 | 11 | 0.010 |
Why?
|
| Phytohemagglutinins | 1 | 1989 | 22 | 0.010 |
Why?
|
| Glycosylphosphatidylinositols | 1 | 1989 | 8 | 0.010 |
Why?
|
| Type C Phospholipases | 1 | 1989 | 28 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1989 | 173 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 1989 | 154 | 0.010 |
Why?
|
| Glycosylation | 1 | 1989 | 129 | 0.010 |
Why?
|
| Cricetinae | 1 | 1989 | 560 | 0.000 |
Why?
|
| United States | 1 | 2000 | 6582 | 0.000 |
Why?
|
| Antigens, CD | 1 | 1989 | 459 | 0.000 |
Why?
|
| Protein Conformation | 1 | 1989 | 881 | 0.000 |
Why?
|
| Neurons | 1 | 1994 | 1547 | 0.000 |
Why?
|